Activity from announced rounds
Global Brain is a Japanese investment corporation, also recorded under the expanded name Global Brain Corporation.
The firm’s own announcements connect it to WED’s receipt-based marketing and RegCell’s cell therapies for autoimmune disease. Other covered activity includes 10pct.’s combination of hotel operations and AI software. Named corporate and flagship funds remain separate.
RegCell is developing cell therapies for autoimmune disease by epigenetically reprogramming pathogenic conventional T cells into stable regulatory T cells, aiming to restore immune tolerance without gene engineering; its platform is advancing toward clinical development.